ERBB2 and sarcoma: Recently, the team conducted a phase I clinical study (ClinicalTrials.gov ID: NCT00902044) on HER2 positive advanced sarcoma patients found that the combination of fludarabine and cyclophosphamide with lymphocyte clearance significantly increased the expansion and duration of HER2 CAR-T cells.